Xinzeyuan Raises US$ 14M in Series B+ Financing to Advance Supply Chain for Minimally Invasive Surgical Devices

Xinzeyuan Medical (鑫泽源医疗), a leading minimally invasive surgical supply chain platform company based in Hangzhou, China, has successfully closed a Series B+ financing round, raising nearly RMB 100 million (US$ 14 million). The round was jointly led by Shunbai Fund and Sanmei Investment, with participation from existing shareholder Qiming Venture Partners.

After completing a Series B financing round led by Qiming Venture Partners in July last year, Xinzeyuan has now secured two financing rounds of more than RMB 100 million within six months, demonstrating its strong market confidence and financing capacity.

Founded in 2015, Xinzeyuan specializes in providing full-chain supply solutions for minimally invasive surgical medical devices. The company covers areas such as endoscopes, endoscopic consumables, minimally invasive surgical instruments, and more. Xinzeyuan is committed to offering CDMO-level services to its clients. Currently, the company’s domestic business has expanded to over 400 medical device enterprises, earning widespread recognition from both domestic and international medical device leaders. Xinzeyuan’s sales network covers more than 20 countries and regions, including the United States, Germany, India, and Russia.

Wang Qiurong (王秋荣), Chairman of Xinzeyuan, said, “We deeply appreciate the trust and support from both new and existing shareholders. As domestic companies continue to rise, Xinzeyuan, leveraging its deep technical expertise and product understanding, is driving innovation and has established itself as a leading supply chain platform for minimally invasive medical devices, integrating capabilities in precision machining, polymer materials, structural design and process engineering.”